Showing 501-510 of 7860 results for "".
The Importance of Being Thorough
https://practicaldermatology.com/topics/practice-management/the-importance-of-being-thorough/19027/Kristina Goldenberg, MD talks about lessons learned in residency, particularly the importance being thorough with patients.Derm Insider: Ethics and Industry: How to Manage Relationships with Pharma
https://practicaldermatology.com/topics/practice-management/derm-insider-ethics-and-industry-how-to-manage-relationships-with-pharma/19029/In this edition, host Neal Bhatia, MD and guests Tom Prunty and James Q. Del Rosso, DO tackle the ethics of industry relationships. They discuss the nuances and challenges of physicians fostering appropriate relationships with pharmaceutical manufacturers amid an increasingly stringent regulatory laPROLITE III, IPL System by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/prolite-iii-ipl-system-by-quantel-derma/19374/PROLITE III by Quantel Derma - The Right Choice for the Right Pulse. The powerful intense pulsed light system (IPL) - high-speed treatments for photo rejuvenation and permanent hair removal. An effective contact cooling is integrated in the handpieces. A variable pulse formation makes PROLITE III exUnderstanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/understanding-the-effect-of-targeting-il-17af-in-psoriatic-arthritis/56663/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Naeim T. Issa, MD, PhD, FAAD, continue their discussion of the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective,” focusinAddressing Itch in Prurigo Nodularis Clinical Trials
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37170/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, addresses how future prurigo nodularis trials could better address the heterogeneity in disease burden and patient-reported outcomes.Innovation in Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/innovation-in-androgenetic-alopecia/54265/Diana Harbort, President of Cosmo Pharmaceuticals' Dermatology Division, discusses the need for new innovations in androgenetic alopecia and the promise of clascoterone for treating the condition.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaIL-31’s Role in Prurigo Nodularis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.Effector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urImproving Care Options for CTCL
https://practicaldermatology.com/series/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.